- Home
- RXT vs DBVT Comparison
RXT vs DBVT Comparison
Compare RXT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXT
- DBVT
- Stock Information
- Founded
- RXT 1998
- DBVT 2002
- Country
- RXT United States
- DBVT France
- Employees
- RXT N/A
- DBVT N/A
- Industry
- RXT EDP Services
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXT Technology
- DBVT Health Care
- Exchange
- RXT Nasdaq
- DBVT Nasdaq
- Market Cap
- RXT 280.1M
- DBVT 260.5M
- IPO Year
- RXT 2020
- DBVT N/A
- Fundamental
- Price
- RXT $1.44
- DBVT $9.87
- Analyst Decision
- RXT Hold
- DBVT Buy
- Analyst Count
- RXT 5
- DBVT 4
- Target Price
- RXT $1.58
- DBVT $14.81
- AVG Volume (30 Days)
- RXT 1.1M
- DBVT 33.2K
- Earning Date
- RXT 11-11-2025
- DBVT 11-05-2025
- Dividend Yield
- RXT N/A
- DBVT N/A
- EPS Growth
- RXT N/A
- DBVT N/A
- EPS
- RXT N/A
- DBVT N/A
- Revenue
- RXT $2,693,100,000.00
- DBVT $3,800,000.00
- Revenue This Year
- RXT N/A
- DBVT $1,743.46
- Revenue Next Year
- RXT $1.59
- DBVT $1,045.66
- P/E Ratio
- RXT N/A
- DBVT N/A
- Revenue Growth
- RXT N/A
- DBVT N/A
- 52 Week Low
- RXT $1.00
- DBVT $2.21
- 52 Week High
- RXT $3.41
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- RXT 56.67
- DBVT 55.10
- Support Level
- RXT $1.32
- DBVT $9.58
- Resistance Level
- RXT $1.52
- DBVT $10.50
- Average True Range (ATR)
- RXT 0.10
- DBVT 0.51
- MACD
- RXT 0.01
- DBVT 0.07
- Stochastic Oscillator
- RXT 73.33
- DBVT 64.92
About RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.